<DOC>
	<DOCNO>NCT01322932</DOCNO>
	<brief_summary>The purpose study assess adherence , tolerability satisfaction eligible HIV subject switch two- three-pill tenofovir-emtricitabine-efavirenz ( TDF-FTC-EFV ) one-pill TDF-FTC-EFV treatment .</brief_summary>
	<brief_title>Tenofovir , Emtricitabine Efavirenz Late Switch Single Pill : Patients ' Opinion Survey</brief_title>
	<detailed_description>Each eligible patient screen de SHCS database . Each refusal drop-out document . A pre-visit ( V-1 ) schedule informed consent , V0 inclusion ( V-1 V0 may occur day ) , V1 one month post-inclusion V2 4 7 month post-inclusion . V0 , V1 V2 plan regular medical visit . Eligible patient either get cART usual pharmacy accord standard care , take part routine adherence-enhancing program ( adherence subgroup ) run pharmacists outpatient medical clinic . In adherence subgroup , adherence assess electronically MEMS ( Medication event monitoring system ) monitor regular basis .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>patient TDFFTCEFV follow Service Infectious Disease University Hospital Lausanne enrol SHCS patient receive TDFFTCEFV combination ARTs patient TDFFTCEFV le 3 month patient fluent French</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Medication Adherence</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>efavirenz , emtricitabine , tenofovir disoproxil fumarate drug combination [ Substance Name ]</keyword>
	<keyword>efavirenz</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>Patient Satisfaction</keyword>
	<keyword>tenofovir disoproxil fumarate</keyword>
</DOC>